Molecular pathways: Toll-like receptors in the tumor microenvironment-poor prognosis or new therapeutic opportunity

Clinical Cancer Research

Volumn 19, Issue 6, 2013, Pages 1340-1346

  Ridnour, Lisa A ^a   Cheng, Robert Y S ^a   Switzer, Christopher H ^a   Heinecke, Julie L ^a   Ambs, Stefan ^a   Glynn, Sharon ^c   Young, Howard A ^b   Trinchieri, Giorgio ^b   Wink, David A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

852 A; AMP 516; ANTINEOPLASTIC AGENT; ARACHIDONIC ACID; BCG VACCINE; BEVACIZUMAB; CANCER VACCINE; CETUXIMAB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ERLOTINIB; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; IMO 2055; INDUCIBLE NITRIC OXIDE SYNTHASE; ISS 1018; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PLACEBO; POLYADENYLIC POLYURIDYLIC ACID; RINTATOLIMOD; RITUXIMAB; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

BASAL CELL CARCINOMA; BLADDER CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; COLORECTAL CANCER; DISEASE ASSOCIATION; DRUG EFFICACY; FOLLICULAR LYMPHOMA; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; INFLAMMATION; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STROMA; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER;

ARACHIDONIC ACID; CYCLOOXYGENASE 2; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PROGNOSIS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TUMOR MICROENVIRONMENT;

EID: 84875189381     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0408     Document Type: Review

References (66)

1. Li X, Jiang S, Tapping RI. Toll-like receptor signaling in cell proliferation and survival. Cytokine 2010;49:1-9.
2. Sato Y, Goto Y, Narita N, Hoon DS. Cancer cells expressing Toll-like receptors and the tumor microenvironment. Cancer Microenviron 2009;2(Suppl 1):205-14.
3. Ve T, Gay NJ, Mansell A, Kobe B, Kellie S. Adaptors in Toll-like receptor signalling and their potential as therapeutic targets. Curr Drug Targets 2012;13:1360-74.
4. Kong Y, Le Y. Toll-like receptors in inflammation of the central nervous system. Int Immunopharmacol 2011;11:1407-14.
5. Dasu MR, Ramirez S, Isseroff RR. Toll-like receptors and diabetes: a therapeutic perspective. Clin Sci (Lond) 2012;122:203-14.
6. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005;65:5009-14.
7. Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007;133: 1869-81.
8. McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 2006;26:154-8.
9. Thotathil Z, Jameson MB. Early experience with novel immunomodulators for cancer treatment. Expert Opin Investig Drugs 2007;16: 1391-403.
10. Guan Y, Ranoa DR, Jiang S, Mutha SK, Li X, Baudry J, et al. Human TLRs 10 and 1 share common mechanisms of innate immune sensing but not signaling. J Immunol 2010;184:5094-103.
11. Hasan U, Chaffois C, Gaillard C, Saulnier V, Merck E, Tancredi S, et al. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol 2005;174:2942-50.
12. Chaturvedi A, Pierce SK. How location governs toll-like receptor signaling. Traffic 2009;10:621-8.
13. Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 2008;13:859-75.
14. Liu L, Botos I, Wang Y, Leonard JN, Shiloach J, Segal DM, et al. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 2008;320:379-81.
15. Barton GM,Medzhitov R. Toll-like receptors and their ligands. Curr Top Microbiol Immunol 2002;270:81-92.
16. Akira S, Sato S. Toll-like receptors and their signaling mechanisms. Scand J Infect Dis 2003;35:555-62.
17. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007;7: 353-64.
18. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-95.
19. Basith S, Manavalan B, Yoo TH, Kim SG, Choi S. Roles of toll-like receptors in cancer: a double-edged sword for defense and offense. Arch Pharm Res 2012;35:1297-316.
20. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
21. Tewari R, Choudhury SR, Ghosh S, Mehta VS, Sen E. Involvement of TNF-alpha-induced TLR4-NF-kappaB and TLR4-HIF-1alpha feed-forward loops in the regulation of inflammatory responses in glioma. J Mol Med (Berl) 2012;90:67-80.
22. Park HD, Lee Y, Oh YK, Jung JG, Park YW, Myung K, et al. Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation. Oncogene 2011;30:201-11.
23. Sheyhidin I, Nabi G, Hasim A, Zhang RP, Ainiwaer J, Ma H, et al. Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol 2011;17:3745-51.
24. Gonzalez-Reyes S, Marin L, Gonzalez L, Gonzalez LO, del Casar JM, Lamelas ML, et al. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer 2010;10:665.
25. Grimm M, Kim M, Rosenwald A, Heemann U, Germer CT, Waaga-Gasser AM, et al. Toll-like receptor (TLR) 7 and TLR8 expression on CD133+ cells in colorectal cancer points to a specific role for inflammation- induced TLRs in tumourigenesis and tumour progression. Eur J Cancer 2010;46:2849-57.
26. Wang EL, Qian ZR, Nakasono M, Tanahashi T, Yoshimoto K, Bando Y, et al. High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer 2010;102:908-15.
27. Zhang JJ, Wu HS, Wang L, Tian Y, Zhang JH, Wu HL. Expression and significance of TLR4 and HIF-1alpha in pancreatic ductal adenocarcinoma. World J Gastroenterol 2010;16:2881-8.
28. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315: 1650-9.
29. Chen GG, Lee JF, Chan UP, Xu H, Ip PC, Lau WY. Increased apoptosis in infiltrating mononuclear cells of colorectal cancer: a mechanism for tumor escape. Arch Pathol Lab Med 2002;126:686-91.
30. Wang Q, Takei Y, Kobayashi O, Osada T, Watanabe S. Cyclooxygenase 2 modulates killing of cytotoxic T lymphocytes by colon cancer cells. J Clin Biochem Nutr 2009;45:163-70.
31. Glynn SA, Boersma BJ, Dorsey TH, Yi M, Yfantis HG, Ridnour LA, et al. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest 2010;120:3843-54.
32. Glynn SA, Prueitt RL, Ridnour LA, Boersma BJ, Dorsey TM, Wink DA, et al. COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer. BMC Cancer 2010;10:626.
33. Harmey JH, Bucana CD, Lu W, Byrne AM, McDonnell S, Lynch C, et al. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 2002;101:415-22.
34. Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004;104:2224-34.
35. Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A 2012;109:E2110-6.
36. He W, Liu Q, Wang L, Chen W, Li N, Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 2007;44: 2850-9.
37. Srivastava MK, Andersson A, Zhu L, Harris-White M, Lee JM, Dubinett S, et al. Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy 2012;4:291-304.
38. Bulut AS, Erden E, Sak SD, Doruk H, Kursun N, Dincol D. Significance of inducible nitric oxide synthase expression in benign and malignant breast epithelium: an immunohistochemical study of 151 cases. Virchows Arch 2005;447:24-30.
39. Loibl S, Buck A, Strank C, von Minckwitz G, Roller M, Sinn HP, et al. The role of early expression of inducible nitric oxide synthase in human breast cancer. Eur J Cancer 2005;41:265-71.
40. Ridnour LA, Barasch KM, Windhausen AN, Dorsey TH, Lizardo MM, Yfantis HG, et al. Nitric oxide synthase and breast cancer: role of TIMP-1 in NO-mediated Akt activation. PLoS ONE 2012;7:e44081.
41. Switzer CH, Glynn SA, Cheng RY, Ridnour LA, Green JE, Ambs S, et al. S-nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer. Mol Cancer Res 2012; 10:1203-15.
42. Thomas DD, Espey MG, Ridnour LA, Hofseth LJ, Mancardi D, Harris CC, et al. Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci U S A 2004;101:8894-9.
43. Timoshenko AV, Lala PK, Chakraborty C. PGE2-mediated upregulation of iNOS in murine breast cancer cells through the activation of EP4 receptors. Int J Cancer 2004;108:384-9.
44. Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 2009;86:557-66.
45. Voelcker V, Gebhardt C, Averbeck M, Saalbach A, Wolf V, Weih F, et al. Hyaluronan fragments induce cytokine and metalloprotease upregulation in human melanoma cells in part by signalling via TLR4. Exp Dermatol 2008;17:100-7.
46. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006;8:1369-75.
47. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008;205:2235-49.
48. Yoo KH, Lim TJ, Chang SG. Monthly intravesical bacillus Calmette-Guerin maintenance therapy for non-muscle-invasive bladder cancer: 10-year experience in a single institute. Exp Ther Med 2012;3:221-5.
49. Simons MP, O'Donnell MA, Griffith TS. Role of neutrophils in BCG immunotherapy for bladder cancer. Urol Oncol 2008;26:341-5.
50. Ludwig AT, Moore JM, Luo Y, Chen X, Saltsgaver NA, O'Donnell MA, et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res 2004;64:3386-90.
51. Simons MP, Moore JM, Kemp TJ, Griffith TS. Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophils. Infect Immun 2007;75:1265-71.
52. Yuk JM, Shin DM, Song KS, Lim K, Kim KH, Lee SH, et al. Bacillus Calmette-Guerin cell wall cytoskeleton enhances colon cancer radiosensitivity through autophagy. Autophagy 2010;6:46-60.
53. Salaun B, Zitvogel L, Asselin-Paturel C, Morel Y, Chemin K, Dubois C, et al. TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res 2011;71:1607-14.
54. Jasani B, Navabi H, Adams M. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 2009;27:3401-4.
55. Basith S, Manavalan B, Lee G, Kim SG, Choi S. Toll-like receptor modulators: a patent review (2006-2010). Expert Opin Ther Pat 2011; 21:927-44.
56. Panelli MC, Stashower ME, Slade HB, Smith K, Norwood C, Abati A, et al. Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 2007;8:R8.
57. Wolf IH, Smolle J, Binder B, Cerroni L, Richtig E, Kerl H. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 2003;139:273-6.
58. Kidner TB, Morton DL, Lee DJ, Hoban M, Foshag LJ, Turner RR, et al. Combined intralesional bacille Calmette-Guerin (BCG) and topical imiquimod for in-transit melanoma. J Immunother 2012;35: 716-20.
59. Dummer R, Hauschild A, Becker JC, Grob JJ, Schadendorf D, Tebbs V, et al. An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin Cancer Res 2008;14:856-64.
60. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008;27:161-7.
61. Kochling J, Prada J, Bahrami M, Stripecke R, Seeger K, Henze G, et al. Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia. Vaccine 2008;26:4669-75.
62. Guha M. Anticancer TLR agonists on the ropes. Nat Rev Drug Discov 2012;11:503-5.
63. Craft N, Bruhn KW, Nguyen BD, Prins R, Lin JW, Liau LM, et al. The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. J Immunol 2005;175: 1983-90.
64. Itoh T, Celis E. Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice. J Immunother 2005;28:430-7.
65. Rechtsteiner G, Warger T, Osterloh P, Schild H, Radsak MP. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol 2005;174:2476-80.
66. Lu H, Wagner WM, Gad E, Yang Y, Duan H, Amon LM, et al. Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J Immunol 2010;184:5360-7.